Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
BIOLIFE SOLUTIONS INC (BLFS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business"
05/10/2023 8-K Quarterly results
Docs: " "
03/16/2023 8-K Quarterly results
Docs: " "
11/09/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
Docs: " "
05/09/2022 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: " "
08/12/2021 8-K Quarterly results
Docs: " "
03/22/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: " "
08/06/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "BioLife Solutions Announces Second Quarter 2019 Financial Results",
"BioLife Solutions Completes Acquisition of SAVSU Technologies"
05/09/2019 8-K Quarterly results
Docs: "BioLife Solutions Announces First Quarter 2019 Financial Results"
11/13/2018 8-K Quarterly results
Docs: "BioLife Solutions Announces Third Quarter 2018 Financial Results"
08/09/2018 8-K Quarterly results
Docs: "BioLife Solutions Announces Second Quarter 2018 Financial Results",
"Casdin Capital Invests $20 Million in BioLife Solutions to Support Strategic Growth Opportunities"
05/10/2018 8-K Quarterly results
Docs: "BioLife Solutions Announces First Quarter 2018 Financial Results"
11/09/2017 8-K Quarterly results
Docs: "BIoLife Solutions, Inc. Unaudited Condensed Consolidated Statements of Operations Three Months Ended Nine Months Ended September 30, 2017 September 30, 2016 September 30, 2017 September 30, 2016 Revenue $ 2,963 $ 2,135 $ 7,887 $ 5,977 Cost of product sales 1,095 921 2,981 2,565 Gross profit 1,868 1,214 4,906 3,412 Gross margin % 63 % 57 % 62 % 57 % Operating expenses Research and development 293 497 899 1,600 Sales and marketing 489 816 1,547 2,399 General and administrative 1,118 1,039 3,298 3,637 Total operating expenses 1,900 2,352 5,744 7,636 Operating loss Total other income Net loss Net loss attributable to non-controlling interest –– 297 –– 924 Net loss attributable to BioLife Solutions, Inc. Less: Preferred stock dividends –– –– Net loss attributable to common stockholders ..."
08/10/2017 8-K Quarterly results
Docs: "BIoLife Solutions, Inc. Unaudited Condensed Consolidated Statements of Operations Three Months Ended Six Months Ended June 30, 2017 June 30, 2016 June 30, 2017 June 30, 2016 Revenue $ 2,558 $ 1,990 $ 4,924 $ 3,842 Cost of product sales 957 873 1,885 1,644 Gross profit 1,601 1,117 3,039 2,198 Gross margin % 63 % 56 % 62 % 57 % Operating expenses Research and development 319 599 605 1,103 Sales and marketing 546 849 1,059 1,583 General and administrative 1,077 1,263 2,180 2,598 Total operating expenses 1,942 2,711 3,844 5,284 Operating loss Total other income Net loss Net loss attributable to non-controlling interest –– 364 –– 627 Net loss attributable to BioLife Solutions, Inc. $ $ $ $ Basic and diluted net loss per common share attributable to BioLife Solutions, Inc. $ $ $ $ Basic an..."
05/12/2016 8-K Form 8-K - Current report
11/12/2015 8-K Quarterly results
Docs: "Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Product Sales $ 1,631,926 $ 1,243,372 $ 4,629,407 $ 4,520,302 Cost of product sales 658,542 654,978 1,954,752 2,483,199 Gross profit 973,384 588,394 2,674,655 2,037,103 Operating expenses Research and development 329,527 153,328 953,026 513,393 Sales and marketing 677,033 298,263 1,819,778 810,279 General and administrative 1,263,272 1,011,316 3,514,678 2,844,858 Total operating expenses 2,269,832 1,462,907 6,287,482 4,168,530 Operating loss Other income Gain on disposal of property and equipment –– 4,400 –– 4,400 Interest income 4,729 7,658 18,448 12,175 Interest expense –– –– –– Amortization of deferred financing costs –– –– –– Total other income 4,729 12,058 18,448 Net loss Net loss attributable to ..."
08/06/2015 8-K Quarterly results
Docs: "Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Product Sales $ 1,496,759 $ 1,211,900 $ 2,997,481 $ 3,276,930 Cost of product sales 678,111 665,580 1,296,210 1,828,221 Gross profit 818,648 545,320 1,701,271 1,448,709 Operating expenses Research and development 301,334 192,778 623,499 360,065 Sales and marketing 642,490 270,616 1,142,745 512,016 General and administrative 1,030,701 969,799 2,251,406 1,833,542 Total operating expenses 1,974,525 1,433,193 4,017,650 2,705,623 Operating loss Other income Interest income 5,482 4,517 13,719 4,517 Interest expense –– –– –– Amortization of deferred financing costs –– –– –– Total other income 5,482 4,517 13,719 Net loss Net loss attributable to non-controlling interest 156,016 –– 276,799 –– Net Loss attributable to BioLife Solutions..."
05/07/2015 8-K Quarterly results
Docs: "Press release"
03/12/2015 8-K Quarterly results
Docs: "Three Months Ended December 31, Year Ended December 31, 2014 2013 2014 2013 Revenue Product sales $ 1,670,396 $ 2,288,880 $ 6,190,698 $ 8,340,234 Licensing revenue –– –– –– 609,167 Total revenue 1,670,396 2,288,880 6,190,698 8,949,401 Cost of product sales 672,089 1,368,777 3,155,288 5,186,514 Gross profit 998,307 920,103 3,035,410 3,762,887 Operating expenses Research and development 357,707 126,412 871,100 487,816 Sales and marketing 519,467 215,851 1,329,746 841,451 General and administrative 1,125,396 862,591 3,970,254 2,718,977 Total operating expenses 2,002,570 1,204,854 6,171,100 4,048,244 Operating loss Other income 8,650 Net Loss $ $ $ $ Net loss attributable to non-controlling interest –– –– Net loss attributable to BioLife Solutions, Inc. Basic and diluted net loss per comm..."
11/06/2014 8-K Quarterly results
Docs: "Three Months Ended September 30, Nine Months Ended September 30, 2014 2013 2014 2013 Revenue Product sales $ 1,243,372 $ 2,170,491 $ 4,520,302 $ 6,051,354 Licensing revenue –– –– –– 609,167 Total revenue 1,243,372 2,170,491 4,520,302 6,660,521 Cost of product sales 654,978 1,281,634 2,483,199 3,817,737 Gross profit 588,394 888,857 2,037,103 2,842,784 Operating expenses Research and development 153,328 160,528 513,393 361,404 Sales and marketing 298,263 208,080 810,279 625,600 General and administrative 1,011,316 630,342 2,844,858 1,856,386 Total operating expenses 1,462,907 998,950 4,168,530 2,843,390 Operating loss Other income Gain on sale of property and equipment 4,400 –– 4,400 –– Interest income 7,658 –– 12,175 –– Interest expense –– Amortization of deferred financing costs –– Tot..."
08/07/2014 8-K Quarterly results
Docs: "Three Months Ended June 30, Six Months Ended June 30, 2014 2013 2014 2013 Revenue Product sales $ 1,211,900 $ 2,330,018 $ 3,276,930 $ 3,880,863 Licensing revenue –– –– –– 609,167 Total revenue 1,211,900 2,330,018 3,276,930 4,490,030 Cost of product sales 665,580 1,501,575 1,828,221 2,536,103 Gross profit 545,320 828,443 1,448,709 1,953,927 Operating expenses Research and development 192,778 94,908 360,065 200,876 Sales and marketing 270,616 214,762 512,016 417,520 General and administrative 969,799 601,617 1,833,542 1,226,044 Total operating expenses 1,433,193 911,287 2,705,623 1,844,440 Operating income 109,487 Other income Interest income 4,517 –– 4,517 –– Interest expense –– Amortization of deferred financing costs –– Total other income 4,517 Net Loss $ $ $ $ Basic and diluted net ..."
05/08/2014 8-K Quarterly results
Docs: "Press release"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy